Skip to main content
. 2024 Feb 29;10(5):e26767. doi: 10.1016/j.heliyon.2024.e26767

Fig. 7.

Fig. 7

METTL3 is a direct miR-186-5p target (a) The total m6A level in Hep3B cells treated with miR-186-5p mimic or inhibitor. (b) METTL3, METTL14, ALKBH5, and FTO protein expression levels are detected using Western blot analysis. (c) The potential binding sites of miR-186-5p and 3′-UTR of METTL3 mRNA. (d) Luciferase reporter assay with reporter plasmid containing the wild-type or mutant METTL3 3′-UTR and NC, miR-186-5p mimic, and miR-186-5p inhibitor. (e) The protein expression of FSTL5 is detected using Western blot analysis. (f) MeRIP qPCR assay is used to evaluate the m6A level of FSTL5 mRNA. Data represent three separate experiments and are expressed as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.“NC”represents the blank control of“miR-186-5p mimic”. “inhibitor NC″represents the blank control of “miR-186-5p inhibitor”.